VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.

SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has ...

Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025. Additional enrollment continues to advance across ...

Medera has completed patient dosing in Cohort B of its ongoing MUSIC-HFpEF Phase I/IIa study of SRD-002 for heart failure ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3 ...

Dunkin’ added Protein Milk to its menu this week, letting customers boost coffees and lattes with 15 grams of protein. Subway rolled out Protein Pockets, soft tortilla wraps with over 20 grams of ...

The fast food industry continues to evolve, and a number of big changes are coming to fast food restaurants in 2026.

The Canadian Food Inspection Agency is already juggling multiple emergencies and costly climate change impacts and says ...

From floodwaters to fragility - The Maravi Post ...

Tenaya plans to pursue regulatory alignment on TN-201 pivotal studies over the course of 2026 with an update to be released ...